SDIX to Help Egg Producers Meet New FDA Regulatory Challenge

  SDIX to Help Egg Producers Meet New FDA Regulatory Challenge

 Easy Use, Cost-Effective RapidChek® SELECT™ Salmonella Enteritidis Designed
                     Specifically for New FDA Regulation

Business Wire

NEWARK, Del. -- July 12, 2010

SDIX™ (Strategic Diagnostics Inc., d/b/a SDIX, Nasdaq:SDIX), a leading
provider of biotechnology-based products and services for a broad range of
life science, biotechnology, diagnostic, and food safety applications, today
commercially launched the RapidChek® SELECT™ Salmonella Enteritidis testing
system. The new system was designed in coordination with leading experts in
egg safety. It is applicable to both egg and poultry industries. However, it
will specifically help U.S. commercial egg producers comply with the new Food
and Drug Administration (FDA) regulation that requires them to test poultry
houses and eggs for Salmonella Enteritidis (SE).

The new FDA rule became effective July 9, 2010 for commercial egg producers
with over 50,000 laying hens and becomes effective July 9, 2012 for egg
producers with between 3,000 and 49,999 laying hens. The new Rule will affect
approximately 4,000 commercial egg producers in the USA. It is estimated that
47 billion eggs are consumed annually in the U.S. and according to reports
from the USDA and FDA, there are 2.3 million eggs annually contaminated with
Salmonella Enteritidis.

The RapidChek SELECT system is an easy, accurate, flexible, and rapid food
pathogen detection technology. It combines the simplicity of advanced
immuno-based detection system with SDIX’s proprietary, patented phage-based
enrichment media to significantly enhance both the specificity and sensitivity
of the test and to enable improved pathogen detection. The system is designed
to:

  *Make it easier to comply with the new FDA Rule – easy to learn and use,
    fast results, robust detection for a better overall picture of hen house
    cleanliness, layer health, and egg safety
  *Help minimize disruption to daily operations – high accuracy virtually
    eliminates false positives. Ease of use and speed to results reduce
    workflow impacts
  *Help minimize costs – reduces training, labor, operating costs. Reduced
    false positives decreases unneeded egg testing costs

The RapidChek® SELECT™ Salmonella Enteritidis system has been evaluated at
several large egg producers and independent testing laboratories during
development to ensure it meets customer needs. Significant validation work has
already begun and the Company expects to submit the system to the FDA, AOAC
RI, and NPIP for approval and certification during the second half of 2010.

The new testing system is comprised of the RapidChek® SELECT™ Salmonella
Enteritidis detection system for screening environmental drag swags or pooled
eggs and the RapidChek® CONFIRM™ Salmonella Enteritidis immunomagnetic
separation system for confirmation.

Tim Lawruk, SDIX Food Safety Marketing Manager, said, “Commercial egg
producers are faced with significant technical and business challenges as they
strive to meet the FDA’s new requirements for both poultry house and egg
testing. The new RapidChek SELECT Salmonella Enteritidis testing system is
specifically designed to help them meet those challenges and provides SDIX
with an opportunity to leverage its expertise in pathogen detection. The
system offers competitive advantages that include ease of use, low start-up
and operating costs, and a faster time-to-result than other methods. Moreover,
the new system’s high accuracy virtually eliminates false positives and the
harmful business impacts they can have. It enables egg producers to focus more
on their core business of providing safe, high-quality eggs.”

About SDIX (www.sdix.com)

SDIX is a biotechnology company, expert at creating advantage by providing a
broad range of quality, innovative, and effective immuno-solutions to the
pharmaceutical, biotechnology, diagnostics, and food safety markets. For
nearly 20 years, SDIX has developed antibodies which advance its customers’
immuno-based work – reducing time, labor, and costs while increasing accuracy
and reliability of results.

SDIX offers a full suite of integrated immuno-solution capabilities including
assay design, development, and production. In life science markets, SDIX
capabilities are being used to help discover the mechanisms of disease,
facilitate the development of new drugs, and provide mechanisms for rapid
diagnosis.

This news release may contain forward-looking statements reflecting SDIX's
current expectations. When used in this press release, words like
“anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”,
“potential”, “will”, “should”, “project”, “plan” and similar expressions as
they relate to SDIX are intended to identify said forward-looking statements.
Investors are cautioned that all forward-looking statements involve risks and
uncertainties, which may cause actual results to differ from those anticipated
by SDIX at this time. Such risks and uncertainties include, without
limitation, changes in demand for products, the application of our
technologies to various uses, delays in product development, delays in market
acceptance of new products, retention of customers and employees, adequate
supply of raw materials, inability to obtain or delays in obtaining fourth
party or required government approvals, the ability to meet increased market
demand, competition, protection of intellectual property, non-infringement of
intellectual property, seasonality, and other factors more fully described in
SDIX's public filings with the U.S. Securities and Exchange Commission.

Contact:

SDIX
Tim Lawruk
Food Safety Market Manager
302-456-6789
tlawruk@sdix.com
 
Press spacebar to pause and continue. Press esc to stop.